No­vavax says its Covid-19 vac­cine proved 89.3% ef­fec­tive in UK tri­al in­clud­ing vari­ant — while South African re­sults slide low­er

Af­ter play­ing be­hind for much of the Covid-19 vac­cine race, No­vavax has come along with the first ef­fi­ca­cy for its pro­tein-based shot, in­clud­ing one of the first glimpses at how the first gen­er­a­tion of vac­cines per­form against emerg­ing vari­ants.

No­vavax an­nounced its vac­cine was 89.3% ef­fec­tive at stop­ping symp­to­matic Covid-19 in its Phase III study in the UK, as of the first in­ter­im analy­sis. The read­out was based on 62 con­firmed cas­es of symp­to­matic Covid-19, 56 of which came in the place­bo group. On­ly one of the 62 cas­es was deemed se­vere, and al­so oc­curred in the place­bo group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.